Strongbridge Biopharma presents new secondary endpoint data on SONICS trial
Strongbridge Biopharma announced the presentation of new secondary endpoint results from the Phase 3 SONICS study of Recorlev for the potential treatment of endogenous Cushing's syndrome at the 2019 American Association of Clinical Endocrinologists, or AACE, annual scientific and clinical congress. Six-months of maintenance Recorlev therapy led to significant improvements in the clinical signs and symptoms of Cushing's syndrome including acne, hirsutism in women and peripheral edema. A reduction in mean free-testosterone in women, consistent with improvements in clinical signs of hyperandrogenism was observed, and a modest increase in mean free-testosterone in men was observed. Significant mean improvements in patient-reported quality-of-life outcomes were observed and symptoms of depression improved. Recorelv was generally well-tolerated, with 12.8% of patients discontinuing treatment due to an adverse event through the end of the six-month maintenance phase.